Colleen Silk/LinkedIn
Nov 4, 2025, 08:22
Colleen Silk on Novo Nordisk Taking the 2025 Prix Galien US Award
Colleen Silk, Corporate Vice President, Rare Disease at Novo Nordisk, shared on LinkedIn:
”Rare diseases remind us that science must never overlook the few.
Hemophilia B with inhibitors affects only a small number of people, yet its impact is profound.
We are proud to have been recognized as a finalist for the 2025 Prix Galien US Award for Best Orphan/Rare Disease Product.
Novo Nordisk believes that every person—no matter how rare their condition—deserves the best that science can offer.
We’re proud of this recognition and grateful to the Prix Galien Foundation for honoring innovation that makes a real difference.”
More winner stories featured in Hemostasis Today.
-
May 10, 2026, 14:03Educational Grant Opportunities for Post–Secondary Students with Inherited Bleeding Disorders – Irish Haemophilia Society
-
May 10, 2026, 13:49Mona Alfaraj: What’s Special About Inherited Macrothrombocytopenia?
-
May 10, 2026, 12:14Ana Cláudia de Souza: Presenting ÁRTEMIS-Brasil at ESOC 2026
-
May 10, 2026, 12:11Umberto Pensato: SPOTMAP Project and ESCAPE-MeVO Analysis Honored with Awards at ESOC 2026
-
May 10, 2026, 12:05Purusotham Chippala: A Comprehensive Patient and Caregiver Education Guide to Make Stroke Easier
-
May 10, 2026, 11:57Mostafa Meshref: Find Our Research Contributions at ESOC 2026
-
May 10, 2026, 11:39Ruisheng Su: Stroke Timer Is an Early Accept at MICCAI 2026
-
May 10, 2026, 11:24Ali Ahmadi: The Immune Landscape After Ischemic Stroke and How to Advance Toward Effective Therapeutic Strategies
-
May 10, 2026, 11:05Yusra Iqbal: The Clinical Spectrum of Platelet Disorders